Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
TG Therapeutics, Inc. (TGTX) had Income from Continuous Operations of $447.18M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$616.29M |
|
$447.18M |
|
$100.71M |
|
$515.57M |
|
$492.96M |
|
$123.32M |
|
$-15.93M |
|
$107.39M |
|
$107.39M |
|
$447.18M |
|
|
Income from Continuous Operations |
$447.18M |
$447.18M |
|
$447.18M |
|
$123.32M |
|
$123.32M |
|
144.32M |
|
161.41M |
|
$3.10 |
|
$2.77 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|